WO2007065017A3 - Systeme d'administration de liposomes cationiques a oligonucleotides - Google Patents

Systeme d'administration de liposomes cationiques a oligonucleotides Download PDF

Info

Publication number
WO2007065017A3
WO2007065017A3 PCT/US2006/046298 US2006046298W WO2007065017A3 WO 2007065017 A3 WO2007065017 A3 WO 2007065017A3 US 2006046298 W US2006046298 W US 2006046298W WO 2007065017 A3 WO2007065017 A3 WO 2007065017A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide
delivery system
liposomal delivery
cationic liposomal
cationic
Prior art date
Application number
PCT/US2006/046298
Other languages
English (en)
Other versions
WO2007065017A2 (fr
Inventor
Neal Clifford Goodwin
Viktor Peykov
Wendi Rodrigueza
Sydney Ugwu
Tong Xuan
Original Assignee
Pronai Therapeutics Inc
Neal Clifford Goodwin
Viktor Peykov
Wendi Rodrigueza
Sydney Ugwu
Tong Xuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronai Therapeutics Inc, Neal Clifford Goodwin, Viktor Peykov, Wendi Rodrigueza, Sydney Ugwu, Tong Xuan filed Critical Pronai Therapeutics Inc
Publication of WO2007065017A2 publication Critical patent/WO2007065017A2/fr
Publication of WO2007065017A3 publication Critical patent/WO2007065017A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositions et des méthodes visant à inhiber l'expression génique. Cette invention concerne en particulier des oligonucléotides séquestrés dans des liposomes cationiques servant au traitement du cancer.
PCT/US2006/046298 2005-12-01 2006-12-01 Systeme d'administration de liposomes cationiques a oligonucleotides WO2007065017A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US74123105P 2005-12-01 2005-12-01
US74122705P 2005-12-01 2005-12-01
US60/741,231 2005-12-01
US60/741,227 2005-12-01
US77831506P 2006-03-02 2006-03-02
US77830506P 2006-03-02 2006-03-02
US60/778,305 2006-03-02
US60/778,315 2006-03-02

Publications (2)

Publication Number Publication Date
WO2007065017A2 WO2007065017A2 (fr) 2007-06-07
WO2007065017A3 true WO2007065017A3 (fr) 2007-09-20

Family

ID=38092900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046298 WO2007065017A2 (fr) 2005-12-01 2006-12-01 Systeme d'administration de liposomes cationiques a oligonucleotides

Country Status (1)

Country Link
WO (1) WO2007065017A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
JP5122474B2 (ja) 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
EP4031191A4 (fr) * 2019-09-18 2023-10-25 The Regents of the University of California Nanoliposomes produisant des protéines et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014172A1 (fr) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition de l'expression de la proteine bcl-2 par des nucleotides olidodesoxy antisens se presentant sous forme de liposomes
WO2002092617A1 (fr) * 2001-05-17 2002-11-21 Avi Biopharma, Inc. Approche combinee du traitement du cancer au moyen d'un oligomere antisens de c-myc
WO2004035523A1 (fr) * 2002-10-16 2004-04-29 Neopharm, Inc. Analogues de cardiolipine cationiques et utilisation de ceux-ci
WO2005067632A2 (fr) * 2004-01-07 2005-07-28 Neopharm, Inc. Compositions lipidiques et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014172A1 (fr) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition de l'expression de la proteine bcl-2 par des nucleotides olidodesoxy antisens se presentant sous forme de liposomes
WO2002092617A1 (fr) * 2001-05-17 2002-11-21 Avi Biopharma, Inc. Approche combinee du traitement du cancer au moyen d'un oligomere antisens de c-myc
WO2004035523A1 (fr) * 2002-10-16 2004-04-29 Neopharm, Inc. Analogues de cardiolipine cationiques et utilisation de ceux-ci
WO2005067632A2 (fr) * 2004-01-07 2005-07-28 Neopharm, Inc. Compositions lipidiques et leurs utilisations

Also Published As

Publication number Publication date
WO2007065017A2 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
WO2007064857A3 (fr) Formulation de liposomes amphoteres
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2007031319A8 (fr) Compositions comprenant des oligonucleotides d'arn a immunostimulation et procedes pour produire lesdits oligonucleotides d'arn
WO2007095316A3 (fr) Compositions et procédés pour formulations à base d'oligonucléotides
WO2008137867A3 (fr) Compositions comportant des agents thérapeutiques mir34 pour traiter le cancer
WO2004111192A3 (fr) Liberation ciblee sur des cellules exprimant la legumaine
WO2008034122A3 (fr) Segments de liaison biodégradables à base d'ester encombré pour distribution d'oligonuclotides
WO2007099377A3 (fr) Traitements contre le cancer
WO2005079397A3 (fr) Molecules d'oligonucleotides anti-microarn
WO2009043353A3 (fr) Oligonucléotides micromir
WO2007042554A3 (fr) Methodes et compositions permettant de traiter des troubles immunitaires
WO2007011962A3 (fr) Traitement du cancer
WO2006113679A3 (fr) Administration d'arnsi par compositions lipidiques neutres
EP1981527A4 (fr) Administration thermiquement ciblee de medicaments comme la doxorubicine
WO2011038160A3 (fr) Compositions et procédés pour réduire au silence des gènes exprimés dans le cancer
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
WO2008042973A3 (fr) Formulations contenant un lipide
WO2006099169A3 (fr) Nouvelles compositions de liposomes
WO2005079533A3 (fr) Procedes et compositions de mediation du silençage genique
WO2007098611A8 (fr) Compositions destinee au traitement des cancers
WO2008141308A3 (fr) Expression génique et douleur
WO2009074970A3 (fr) Moyen de diffusion d'acides nucleiques actifs dans le silencage genique au moyen de polymeres synthetiques
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2008045576A3 (fr) Compositions et procédés dans lesquels sont utilisés des agents thérapeutiques à base d'arni, destinés au traitement du cancer et d'autres maladies liées à la néovascularisation
WO2011072292A3 (fr) Formulations à changement de phase d'arn et de dérivés d'arn

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06838962

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06838962

Country of ref document: EP

Kind code of ref document: A2